{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044598","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.093373+00:00","generated_at":"2026-06-07T14:23:15.200135+00:00","sec_items":["1.01","3.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Calidi Biotherapeutics enters $25M equity line with Yorkville; director resignation and replacement","bullets":["SEPA provides up to $25M (expandable to $50M) of common stock at 97% of market price over 36 months.","Commitment fee of $250,000 in shares and $25,000 structuring fee; advance capped at 5M shares or 100% of 5-day avg volume.","Director Thomas Vecchiolla resigns effective Jan 1, 2024; David LaPre appointed to fill vacancy as independent director.","Issuance capped at 19.99% of outstanding shares unless shareholder approval or price test met; requires effective registration statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044598","json":"https://secwatch.observer/filing/0001493152-23-044598.json","markdown":"https://secwatch.observer/filing/0001493152-23-044598.md","text":"https://secwatch.observer/filing/0001493152-23-044598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:23:15.200135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"031b845b19","claim":"David LaPre was appointed as Director at Calidi Biotherapeutics, Inc..","evidence_excerpt":"the Board appointed Mr. David LaPre as a director to fill the vacancy in connection with Mr. Vecchiolla’s departure, effective January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ca2786eb7e","claim":"Thomas Vecchiolla resigned as Director at Calidi Biotherapeutics, Inc..","evidence_excerpt":"Mr. Thomas Vecchiolla announced that he will be resigning as a director of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) effective January 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f79be0a48b122338701ff53df237bebad64cd212","claim":"Calidi Biotherapeutics, Inc. entered into Standby Equity Purchase Agreement with YA II PN, Ltd. valued at up to $25,000,000 (effective 2023-12-10).","evidence_excerpt":"On December 10, 2023, Calidi Biotherapeutics, Inc. (the “Company”) entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd., a Cayman Island exempt limited partnership (“Yorkville”). Pursuant to the SEPA, the Company will have the right, but not the obligation, to sell to Yorkville up to $25,000,000 of its shares of Common Stock, par value $0.0001 per share (the “Common Stock”), at the Company’s request any time during the 36 months following the execution of the SEPA.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315223044598/0001493152-23-044598-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"YA II PN, Ltd."},{"label":"Value","value":"up to $25,000,000"},{"label":"Effective","value":"2023-12-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}